Certain components used in the packaging of GAMMAGARD S/D contain natural rubber latex.
IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin reaction and, rarely, hemolysis.
Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization.
Various minor reactions, such as mild to moderate hypotension, headache, fatigue, chills, backache, leg cramps, lightheadedness, fever, urticaria, flushing, slight elevation of blood pressure, nausea and vomiting may occasionally occur.
The potential risks and benefits of IGIV should be weighed against those of alternative therapies for all patients for whom IGIV administration is being considered.
For full prescribing information for GAMMAGARD LIQUID, GAMMAGARD S/D and GAMMAGARD S/D with IgA less than 1 microgram/mL in a 5% solution please go to: http://www.baxter.com/products/biopharmaceuticals/downloads/gammagard_us_pi .pd f (To link to this website, please copy and paste URL in Internet browser) http://www.baxter.com/products/biopharmaceuticals/downloads/gamliquid_PI.pd f http://www.immunedisease.com/US/pdfs/gammagardsd_iga.pdf
Baxter International Inc., through its subsidiaries,
|SOURCE Baxter International Inc.|
Copyright©2007 PR Newswire.
All rights reserved